Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐INHIBITION study design

MLA

Magalie Ladouceur, et al. Efficacy of Phosphodiesterase Type 5 Inhibitors in Univentricular Congenital Heart Disease: The SV‐INHIBITION Study Design. Mar. 2020. EBSCOhost, https://doi.org/10.1002/ehf2.12630⟩.

APA

Magalie Ladouceur, Sv-Inhibition study investigators, Marc Humbert, Hamouda Abassi, Caroline Ovaert, Alban-Elouen Baruteau, Arthur Gavotto, Jean-Benoit Thambo, Sébastien Hascoët, P. Aldebert, Alain Fraisse, Sophie Malekzadeh-Milani, Marilyne Lévy, Marie-Christine Picot, Sarah Cohen, Pascal Amedro, Clément Karsenty, Damien Bonnet, & Stefan Matecki. (2020). Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐INHIBITION study design. https://doi.org/10.1002/ehf2.12630⟩

Chicago

Magalie Ladouceur, Sv-Inhibition study investigators, Marc Humbert, Hamouda Abassi, Caroline Ovaert, Alban-Elouen Baruteau, Arthur Gavotto, et al. 2020. “Efficacy of Phosphodiesterase Type 5 Inhibitors in Univentricular Congenital Heart Disease: The SV‐INHIBITION Study Design,” March. doi:10.1002/ehf2.12630⟩.